GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HLB Science Inc (XKRX:343090) » Definitions » Current Deferred Taxes Liabilities

HLB Science (XKRX:343090) Current Deferred Taxes Liabilities : ₩0.00 Mil (As of . 20)


View and export this data going back to 2020. Start your Free Trial

What is HLB Science Current Deferred Taxes Liabilities?

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

HLB Science's current deferred tax liabilities for the quarter that ended in . 20 was ₩0.00 Mil.

HLB Science Current Deferred Taxes Liabilities Historical Data

The historical data trend for HLB Science's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HLB Science Current Deferred Taxes Liabilities Chart

HLB Science Annual Data
Trend Dec22 Dec23
Current Deferred Taxes Liabilities
- -

HLB Science Quarterly Data
Current Deferred Taxes Liabilities

HLB Science Current Deferred Taxes Liabilities Related Terms

Thank you for viewing the detailed overview of HLB Science's Current Deferred Taxes Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


HLB Science (XKRX:343090) Business Description

Industry
Traded in Other Exchanges
N/A
Address
66, Achasan-ro, 6th Floor, Seongdong-gu, Seoul, KOR
HLB Science Inc develops biological new drugs to treat infectious diseases. Its product pipelines includes DD-S052P, DD-A279, and DD-A514.

HLB Science (XKRX:343090) Headlines

No Headlines